- ￥560 - 1000
- MedChemExpress(MCE)
- 美国
- HY-14658
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
50-35-1
- 规格：
10 mM * 1 mL/200 mg/500 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥616.0 |
|---|---|---|---|
| 规格： | 200 mg | 产品价格： | ￥560.0 |
| 规格： | 500 mg | 产品价格： | ￥1000.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Thalidomide
CAS No. : 50-35-1
MCE 国际站：Thalidomide
产品活性：Thalidomide 能够抑制 cereblon (cullin-4 E3 泛素连接酶复合物 CUL4-RBX1-DDB1 的一部分)，Kd 值约为 250 nM，具有免疫调节、抗炎、抗肿瘤作用。Thalidomide 可以作为分子胶来增强底物。
研究领域：PROTAC | Autophagy | Apoptosis | Anti-infection
作用靶点：Ligands for E3 Ligase | Molecular Glues | Autophagy | Apoptosis | Bacterial
In Vitro: Thalidomide has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties, and targets cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ～250 nM.
Thalidomide (50 μg/mL) potentiates the anti-tumor activity of Icotinib against the proliferation of both PC9 and A549 cells, and this effect is correlated with apoptosis and cell migration. In addition, Thalidomide and Icotinib inhibits the EGFR and VEGF-R2 pathways in PC9 cells.
In Vivo: Thalidomide (100 mg/kg, p.o.) inhibits the collagen deposition, down-regulates the mRNA expression level of α-SMA and collagen I, and significantly reduces the pro-inflammatory cytokines in RILF mice. Thalidomide alleviates RILF via suppression of ROS and down-regulation of TGF-β/Smad pathway dependent on Nrf2 status.
Thalidomide (200 mg/kg, p.o.) combined with Icotinib shows synergistic anti-tumor effects in nude mice bearing PC9 cells, suppressing tumor growth and promoting tumor death.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Apoptosis Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | CNS-Penetrant Compound Library | Autophagy Compound Library | Drug Repurposing Compound Library | Antibacterial Compound Library | Ubiquitination Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Rare Diseases Drug Library | Children’s Drug Library | Chemotherapy Drug Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | E3 Ligase Ligand Library | Non-steroidal Anti-Inflammatory Compound Library | Molecular Glue Compound Library | Heterocyclic Compound Library | Withdrawn Drug Compound Library | Off-patent Drug Library | Cell Death Library | MG-132 | Rapamycin | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Dexamethasone | Acetylcysteine | Puromycin dihydrochloride | Angiotensin II human | Dimethyl sulfoxide | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | G-418 disulfate | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验突变表型相似，但本质不同，用生化的方法是可以加以区分的。 在人类中也有很多表型模拟的例子，白内障、耳聋、心脏缺陷等有的是遗传的，也有的是由于患者的母亲在怀孕后2周内感染了麻疹病毒而引起。人类的其他一些性状也有表型模拟，如短肢畸型（phcomelia），这种畸型有的是受显性等位基因控制的，这个基因抑制了四肢长骨的发育。在1959~1961年之间，发现孕妇在妊娠35~50天若服用镇静剂反应停（thalidomide）也会使孩子产生同样的表型，现在这种药物早已被淘汰了。
3.73 3.61 3.51 3.44 3.37 3.28 3.18 3.07 2.96 2.85 2.72 12 13 4.96 4.35 4.00 3.77 3.60 3.48 3.39 3.31 3.25 3.15 3.05 2.95 2.84 2.72 2.59 13 14 4.86 4.24 3.89 3.66 3.50 3.38 3.28 3.21 3.15 3.05 2.95 2.84 2.73 2.61 2.49 14 15 4.76 4.15 3.80
，1000，2000 bp 片段，以 pBS 质粒为模板扩增 1500 bp 片段。 模板：pUC19 质粒 30 ng/50 μL or pBS 质粒 30 ng/50 μL PCR 扩增程序： 循环数 Step 温度 时间 1 1 94 ℃ 2 min 35 1 94 ℃ 45 sec 2 55 ℃ 45 sec 3 72 ℃ 2 min 1 1 72 ℃ 5 min 2．质粒菌液直接扩增： 以 pUC19 菌液为模板扩增 100，250，500，750，1000
技术资料暂无技术资料 索取技术资料
